Paper Details

  1. Home
  2. Paper Details

Efficacy and Safety of Sofosbuvir-Based Direct Acting Antivirals for Hepatitis C in Septuagenarians and Octogenarians.

Author: AliBilal, GonzalezHumberto C, NairSatheesh, SatapathySanjaya K, SnyderHeather S

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study aims to evaluate the efficacy and safety of direct acting antiviral (DAA) agents for the treatment of chronic hepatitis C (HCV) in patients aged 70 years or older. This population is often underrepresented in clinical trials, and the study will help determine the optimal treatment approach for older patients.
Paper Details　
Original Abstract of the Article :
Treatment of chronic hepatitis C (HCV) with newer direct acting antiviral (DAA) agents has been highly effective. Unfortunately, patients over 70 years old are underrepresented in studies. Given current recommendations to screen patients born between 1945 and 1965 for HCV, it is essential to determi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478933/

データ提供：米国国立医学図書館（NLM）

Hepatitis C Treatment in the Elderly: Finding Oasis in a Challenging Terrain

The advent of direct-acting antiviral (DAA) therapies has revolutionized the treatment of chronic hepatitis C (HCV). However, the effectiveness of these therapies in older patients remains an important area of research. This study explores the efficacy and safety of sofosbuvir-based DAAs in septuagenarians and octogenarians, navigating the unique challenges of treating HCV in the elderly.

DAAs for Hepatitis C in Older Adults: Navigating the Terrain

The study findings suggest that sofosbuvir-based DAAs are effective and safe for treating HCV in patients over 70 years old. This is encouraging news, offering a potential oasis of relief for older patients struggling with this chronic condition. It's like finding a reliable trail guide in a challenging desert environment.

Hope for a Healthier Future: DAAs Offer Promise for the Elderly

This research highlights the importance of considering the unique needs of older patients when treating HCV. It provides valuable insights into the safety and efficacy of DAAs in this population, offering a potential path towards a healthier future for older patients.

Dr.Camel's Conclusion

This study offers a ray of hope for older patients with chronic hepatitis C. It's like discovering a hidden wellspring in the desert – a source of relief and healing for those who have long struggled with this condition. The findings demonstrate that DAAs can be a powerful tool in addressing the unique challenges of treating HCV in the elderly.

Date :
  1. Date Completed n.d.
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

28663671

DOI: Digital Object Identifier

PMC5478933

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.